Correction

This article refers to:

Safety and effectiveness of ipragliflozin in elderly versus non-elderly Japanese type 2 diabetes mellitus patients: 12 month interim results of the STELLA-LONG TERM study

Article title: Safety and effectiveness of ipragliflozin in elderly versus non-elderly Japanese type 2 diabetes mellitus patients: 12 month interim results of the STELLA-LONG TERM study

Authors: Maegawa, H., Tobe, K., Nakamura, I., & Uno, S.

Journal: Current Medical Research and Opinion

Bibliometrics: Volume 35, Number 11, pages 1901–1910

DOI: https://doi.org/10.1080/03007995.2019.1647503

This article was first published with an error in Table 3. The correct version of Table 3 is:

Data are presented as n (%) unless otherwise stated. The dash indicates that no p value was calculated when at least one element of the contingency table was less than 10.

Abbreviation. ADR, Adverse drug reaction.

The error has been corrected and the article has been re-published. 

Table 3. ADRs, serious ADRs and ADRs of special interest.

	Pre-approval n = 1669	STELLA-LONG TERM				STELLA-ELDER n (%)
		All	<65 years	≥65 years	p value
		n = 11,051	n = 7894	n = 3157	(chi-squared test)
ADRs	549 (32.89)	1616 (14.6)	1169 (14.8)	447 (14.2)	.383	1438 (16.9)
Serious ADRs	14 (0.8)	107 (1.0)	62 (0.8)	45 (1.4)	.002	127(1.5)
Hypoglycemia	22 (1.4)	39 (0.4)	22 (0.3)	17 (0.5)	.037	58 (0.7)
Genital infection	32 (2.0)	135 (1.2)	107 (1.4)	28 (0.9)	.043	166 (2.0)
Urinary tract infection	29 (1.8)	115 (1.0)	77 (1.0)	38 (1.2)	.285	118 (1.4)
Polyuria/pollakiuria	163 (10.0)	571 (5.2)	450 (5.7)	121 (3.8)	<.001	170 (2.0)
Volume depletion	73 (4.5)	196 (1.8)	138 (1.8)	58 (1.8)	.749	266 (3.1)
Renal disorder	76 (4.6)	115 (1.0)	71 (0.9)	44 (1.4)	.021	118 (1.4)
Hepatic disorder	17 (1.0)	82 (0.7)	71 (0.9)	11 (0.4)	.002	19 (0.2)
Fracture	0	2 (0.02)	2 (0.03)	0 (0.00)	–	2 (0.02)
Malignant tumor	4 (0.2)	22 (0.2)	12 (0.2)	10 (0.3)	.079	11 (0.1)
Cardiovascular disease	16 (1.0)	30 (0.3)	23 (0.3)	7 (0.2)	–	24 (0.3)
Cerebrovascular disease	4 (0.2)	23 (0.2)	13 (0.2)	10 (0.3)	.113	36 (0.4)
Skin complications	59 (3.5)	166 (1.5)	104 (1.3)	62 (2.0)	.012	269 (3.2)
Ketone body-related events	11 (0.7)	3 (0.03)	3 (0.04)	0 (0.00)	–	2 (0.02)